vs
Side-by-side financial comparison of PETMED EXPRESS INC (PETS) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.
PETMED EXPRESS INC is the larger business by last-quarter revenue ($40.7M vs $20.6M, roughly 2.0× Entrada Therapeutics, Inc.). PETMED EXPRESS INC runs the higher net margin — -26.0% vs -84.4%, a 58.4% gap on every dollar of revenue. On growth, PETMED EXPRESS INC posted the faster year-over-year revenue change (-23.3% vs -65.2%). PETMED EXPRESS INC produced more free cash flow last quarter ($-9.2M vs $-39.7M). Over the past eight quarters, Entrada Therapeutics, Inc.'s revenue compounded faster (6.4% CAGR vs -20.9%).
PetMed Express, Inc., also known as PetMeds, is an online pet pharmacy based in the United States. It is publicly traded and sells prescription and non-prescription pet medication.
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
PETS vs TRDA — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $40.7M | $20.6M |
| Net Profit | $-10.6M | $-17.3M |
| Gross Margin | 23.3% | — |
| Operating Margin | -25.7% | -106.0% |
| Net Margin | -26.0% | -84.4% |
| Revenue YoY | -23.3% | -65.2% |
| Net Profit YoY | -1392.6% | -173.8% |
| EPS (diluted) | $-0.50 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $40.7M | — | ||
| Q3 25 | $44.4M | — | ||
| Q2 25 | $51.2M | — | ||
| Q1 25 | $50.8M | $20.6M | ||
| Q4 24 | $52.0M | $37.4M | ||
| Q3 24 | $58.0M | $19.6M | ||
| Q2 24 | $66.2M | $94.7M | ||
| Q1 24 | $65.1M | $59.1M |
| Q4 25 | $-10.6M | — | ||
| Q3 25 | $-8.5M | — | ||
| Q2 25 | $-34.2M | — | ||
| Q1 25 | $-11.6M | $-17.3M | ||
| Q4 24 | $-707.0K | $1.1M | ||
| Q3 24 | $2.3M | $-14.0M | ||
| Q2 24 | $3.8M | $55.0M | ||
| Q1 24 | $-5.0M | $23.5M |
| Q4 25 | 23.3% | — | ||
| Q3 25 | 28.0% | — | ||
| Q2 25 | 28.1% | — | ||
| Q1 25 | 29.9% | — | ||
| Q4 24 | 31.0% | — | ||
| Q3 24 | 32.3% | — | ||
| Q2 24 | 28.8% | — | ||
| Q1 24 | 29.3% | — |
| Q4 25 | -25.7% | — | ||
| Q3 25 | -18.9% | — | ||
| Q2 25 | -66.7% | — | ||
| Q1 25 | -11.9% | -106.0% | ||
| Q4 24 | -0.9% | -15.7% | ||
| Q3 24 | 1.0% | -110.7% | ||
| Q2 24 | 6.6% | 56.4% | ||
| Q1 24 | -5.9% | 35.7% |
| Q4 25 | -26.0% | — | ||
| Q3 25 | -19.2% | — | ||
| Q2 25 | -66.7% | — | ||
| Q1 25 | -22.9% | -84.4% | ||
| Q4 24 | -1.4% | 3.0% | ||
| Q3 24 | 4.0% | -71.7% | ||
| Q2 24 | 5.7% | 58.1% | ||
| Q1 24 | -7.7% | 39.7% |
| Q4 25 | $-0.50 | — | ||
| Q3 25 | $-0.41 | — | ||
| Q2 25 | $-1.65 | — | ||
| Q1 25 | $-0.56 | $-0.42 | ||
| Q4 24 | $-0.03 | $-0.20 | ||
| Q3 24 | $0.11 | $-0.35 | ||
| Q2 24 | $0.18 | $1.55 | ||
| Q1 24 | $-0.24 | $0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $26.9M | $67.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $32.8M | $417.3M |
| Total Assets | $88.0M | $486.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $26.9M | — | ||
| Q3 25 | $36.1M | — | ||
| Q2 25 | $41.1M | — | ||
| Q1 25 | $54.7M | $67.8M | ||
| Q4 24 | $50.1M | $101.2M | ||
| Q3 24 | $52.0M | $78.0M | ||
| Q2 24 | $46.0M | $185.3M | ||
| Q1 24 | $55.3M | $68.4M |
| Q4 25 | $32.8M | — | ||
| Q3 25 | $43.1M | — | ||
| Q2 25 | $51.5M | — | ||
| Q1 25 | $85.1M | $417.3M | ||
| Q4 24 | $96.2M | $428.7M | ||
| Q3 24 | $96.4M | $422.4M | ||
| Q2 24 | $93.5M | $429.9M | ||
| Q1 24 | $96.7M | $269.4M |
| Q4 25 | $88.0M | — | ||
| Q3 25 | $100.3M | — | ||
| Q2 25 | $109.8M | — | ||
| Q1 25 | $148.7M | $486.5M | ||
| Q4 24 | $144.8M | $526.3M | ||
| Q3 24 | $146.0M | $554.6M | ||
| Q2 24 | $152.7M | $582.0M | ||
| Q1 24 | $169.9M | $510.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-9.2M | $-38.5M |
| Free Cash FlowOCF − Capex | $-9.2M | $-39.7M |
| FCF MarginFCF / Revenue | -22.7% | -192.9% |
| Capex IntensityCapex / Revenue | 0.1% | 5.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-23.0M | $-58.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-9.2M | — | ||
| Q3 25 | $-2.2M | — | ||
| Q2 25 | $-12.3M | — | ||
| Q1 25 | $7.0M | $-38.5M | ||
| Q4 24 | $-1.2M | $-31.6M | ||
| Q3 24 | $7.4M | $-24.3M | ||
| Q2 24 | $-8.5M | $39.8M | ||
| Q1 24 | $7.1M | $-25.5M |
| Q4 25 | $-9.2M | — | ||
| Q3 25 | $-4.8M | — | ||
| Q2 25 | $-13.6M | — | ||
| Q1 25 | $4.6M | $-39.7M | ||
| Q4 24 | $-1.9M | $-32.2M | ||
| Q3 24 | $6.1M | $-24.9M | ||
| Q2 24 | $-9.2M | $38.8M | ||
| Q1 24 | $5.9M | $-26.4M |
| Q4 25 | -22.7% | — | ||
| Q3 25 | -10.8% | — | ||
| Q2 25 | -26.5% | — | ||
| Q1 25 | 9.1% | -192.9% | ||
| Q4 24 | -3.7% | -86.2% | ||
| Q3 24 | 10.6% | -127.3% | ||
| Q2 24 | -13.9% | 41.0% | ||
| Q1 24 | 9.0% | -44.6% |
| Q4 25 | 0.1% | — | ||
| Q3 25 | 5.9% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | 4.7% | 5.6% | ||
| Q4 24 | 1.5% | 1.7% | ||
| Q3 24 | 2.2% | 3.3% | ||
| Q2 24 | 1.0% | 1.1% | ||
| Q1 24 | 1.9% | 1.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -27.94× | ||
| Q3 24 | 3.18× | — | ||
| Q2 24 | -2.27× | 0.72× | ||
| Q1 24 | — | -1.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PETS
| Reorder | $34.0M | 84% |
| New Order | $5.0M | 12% |
| Membership Fees | $1.6M | 4% |
TRDA
Segment breakdown not available.
